News Sentiment

STRO sentiment intelligence

Sutro Biopharma news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 57 Balanced news tone 69 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 29.73 Week of 10 Jul 2026
Weighted tone 57/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

77/100 classification confidence.

Company focus 60

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend active

-2.3% over one week, +3.2% over four weeks, trend active, and near fair-value range.

Latest direct headline Positive

Sutro Biopharma (STRO) TD Cowen 46th Annual Health Care Conference Summary

Market Reaction

Balanced read

65/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 77/100 classification
One-week reaction -2.3% Price reacting lower
Trend fit Trend active 3.2% over four weeks
Fair value 13.0% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 27
Neutral 35
Negative 7

Relevance

Why the article matched

Direct first
Direct company coverage 60
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 12
Market source 8
TradingView 6
TradingKey 6
MT Newswires 4
simplywall.st 4
Quartr 3
Moomoo 3

Event Lens

What the news is about

Classified themes
Market update 31
Earnings 19
Analyst action 13
Balance sheet 3
Deals and strategy 2
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 69
Finviz Direct company coverage

STRO - Sutro Biopharma Inc Stock Price and Quote

This article provides comprehensive financial data, stock performance metrics, and analyst ratings for Sutro Biopharma Inc. (STRO). It details insider transactions, company leadership information, and a timeline of news events related to the company's clinical trials, financial r

Tone
Positive 62/100
Event
Analyst action
Published
04 Jun 2026 07:40
Source
Finviz
Stock Titan Direct company coverage

Sutro Biopharma (STRO) CFO exercises 2,500 RSUs and increases direct holdings

Sutro Biopharma's CFO, Gregory K. Chow, exercised 2,500 Restricted Stock Units (RSUs) on June 2, 2026, increasing his direct holdings to 4,725 shares of Common Stock and retaining 7,500 RSUs. This transaction was a compensation-related exercise with no shares sold, and tax liabil

Tone
Neutral 50/100
Event
Market update
Published
02 Jun 2026 20:40
Source
Stock Titan
The Globe and Mail Direct company coverage

Barclays Initiates a Buy Rating on Sutro Biopharma (STRO)

Barclays has initiated a Buy rating on Sutro Biopharma (STRO) with a price target. This follows a recent Buy rating from H.C. Wainwright, although Bank of America Securities reiterated a Sell rating. For the quarter ending March 31, Sutro Biopharma reported $14.52 million in reve

Tone
Positive 76/100
Event
Analyst action
Published
29 May 2026 09:09
Source
The Globe and Mail